Home Healthcare Pharmaceuticals Anti-HIV Drugs Market

Anti-HIV Drugs Market Size, Share & Trends Analysis Report By Medication Class (Multi-class combination drugs, Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), HIV integrase strand transfer inhibitors), By Distribution Channel (Hospital pharmacies, Retail pharmacies, E-commerce) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR773DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-HIV Drugs Market, By Medication Class 2022-2034 (USD MILLION/ Units)
    1. Multi-class combination drugs
    2. Nucleoside reverse transcriptase inhibitors (NRTIs)
    3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
    4. HIV integrase strand transfer inhibitors
  2. Anti-HIV Drugs Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital pharmacies
    2. Retail pharmacies
    3. E-commerce
  3. Regional Anti-HIV Drugs Market
    1. North America
      1. North America Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. North America Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. U.S. Anti-HIV Drugs Market
        1. U.S. Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. U.S. Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      4. Canada Anti-HIV Drugs Market
        1. Canada Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Canada Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
    2. Europe
      1. Europe Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. Europe Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. U.K. Anti-HIV Drugs Market
        1. U.K. Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. U.K. Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      4. Germany Anti-HIV Drugs Market
        1. Germany Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Germany Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      5. France Anti-HIV Drugs Market
        1. France Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. France Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      6. Spain Anti-HIV Drugs Market
        1. Spain Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Spain Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      7. Italy Anti-HIV Drugs Market
        1. Italy Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Italy Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      8. Russia Anti-HIV Drugs Market
        1. Russia Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Russia Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      9. Nordic Anti-HIV Drugs Market
        1. Nordic Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Nordic Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      10. Benelux Anti-HIV Drugs Market
        1. Benelux Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Benelux Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      11. Rest of Europe Anti-HIV Drugs Market
        1. Rest of Europe Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Rest of Europe Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
    3. APAC
      1. APAC Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. APAC Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. China Anti-HIV Drugs Market
        1. China Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. China Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      4. Korea Anti-HIV Drugs Market
        1. Korea Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Korea Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      5. Japan Anti-HIV Drugs Market
        1. Japan Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Japan Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      6. India Anti-HIV Drugs Market
        1. India Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. India Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      7. Australia Anti-HIV Drugs Market
        1. Australia Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Australia Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      8. Taiwan Anti-HIV Drugs Market
        1. Taiwan Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Taiwan Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      9. South East Asia Anti-HIV Drugs Market
        1. South East Asia Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. South East Asia Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      10. Rest of Asia-Pacific Anti-HIV Drugs Market
        1. Rest of Asia-Pacific Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Rest of Asia-Pacific Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
    4. Middle East and Africa
      1. Middle East and Africa Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. Middle East and Africa Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. UAE Anti-HIV Drugs Market
        1. UAE Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. UAE Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      4. Turkey Anti-HIV Drugs Market
        1. Turkey Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Turkey Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      5. Saudi Arabia Anti-HIV Drugs Market
        1. Saudi Arabia Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Saudi Arabia Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      6. South Africa Anti-HIV Drugs Market
        1. South Africa Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. South Africa Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      7. Egypt Anti-HIV Drugs Market
        1. Egypt Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Egypt Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      8. Nigeria Anti-HIV Drugs Market
        1. Nigeria Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Nigeria Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      9. Rest of MEA Anti-HIV Drugs Market
        1. Rest of MEA Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Rest of MEA Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
    5. LATAM
      1. LATAM Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
        1. Multi-class combination drugs
        2. Nucleoside reverse transcriptase inhibitors (NRTIs)
        3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
        4. HIV integrase strand transfer inhibitors
      2. LATAM Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital pharmacies
        2. Retail pharmacies
        3. E-commerce
      3. Brazil Anti-HIV Drugs Market
        1. Brazil Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Brazil Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      4. Mexico Anti-HIV Drugs Market
        1. Mexico Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Mexico Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      5. Argentina Anti-HIV Drugs Market
        1. Argentina Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Argentina Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      6. Chile Anti-HIV Drugs Market
        1. Chile Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Chile Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      7. Colombia Anti-HIV Drugs Market
        1. Colombia Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Colombia Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
      8. Rest of LATAM Anti-HIV Drugs Market
        1. Rest of LATAM Anti-HIV Drugs Market By Medication Class 2022-2034 (USD MILLION/ Units)
          1. Multi-class combination drugs
          2. Nucleoside reverse transcriptase inhibitors (NRTIs)
          3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
          4. HIV integrase strand transfer inhibitors
        2. Rest of LATAM Anti-HIV Drugs Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital pharmacies
          2. Retail pharmacies
          3. E-commerce
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.